SEHK:1093Pharmaceuticals
Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After New Autoimmune And Nephrology Drug Approvals
CSPC Pharmaceutical Group (SEHK:1093) has recently secured Chinese approvals for Enyike, a ustekinumab biosimilar, and 4mg budesonide enteric-coated capsules, broadening its autoimmune and nephrology treatment offerings for patients.
See our latest analysis for CSPC Pharmaceutical Group.
At a latest share price of HK$7.69, the stock has seen a 1-day share price return of 4.77% and a 7-day share price return of 1.45%, but a 90-day share price return that is down 23.56%. The 1-year total...